P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE...

por Gupta, V., Mascarenhas, J., Kremyanskaya, M., Rampal, R. K., Talpaz, M., Kiladjian, J.-J., Vannucchi, A., Verstovsek, S., Colak, G., Dey, D., Harrison, C.
Publicado 2022

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

por Padron, E, Garcia-Manero, G, Patnaik, M M, Itzykson, R, Lasho, T, Nazha, A, Rampal, R K, Sanchez, M E, Jabbour, E, Al Ali, N H, Thompson, Z, Colla, S, Fenaux, P, Kantarjian, H M, Killick, S, Sekeres, M A, List, A F, Onida, F, Komrokji, R S, Tefferi, A, Solary, E
Publicado 2015

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYEL...

por Harrison, C., Rampal, R. K., Gupta, V., Verstovsek, S., Talpaz, M., Kiladjian, J.-J., Mesa, R., Kuykendall, A., Vannucchi, A., Palandri, F., Grosicki, S., Devos, T., Jourdan, E., Wondergem, M. J., Al-Ali, H. K., Buxhofer-Ausch, V., Alvarez-Larrán, A., Akhani, S., Muñoz-Carerras, R., Sheykin, Y., Colak, G., Harris, M., Mascarenhas, J.
Publicado 2022